Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-23-032298
Filing Date
2023-07-10
Accepted
2023-07-07 18:55:53
Documents
80
Period of Report
2023-04-30

Document Format Files

Seq Description Document Type Size
1 10-K kalv-20230430.htm   iXBRL 10-K 2988539
2 EX-23.1 kalv-ex23_1.htm EX-23.1 3854
3 EX-31.1 kalv-ex31_1.htm EX-31.1 22191
4 EX-31.2 kalv-ex31_2.htm EX-31.2 17386
5 EX-32.1 kalv-ex32_1.htm EX-32.1 9119
6 EX-32.2 kalv-ex32_2.htm EX-32.2 11771
  Complete submission text file 0000950170-23-032298.txt   10021636

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kalv-20230430_lab.xml EX-101.LAB 474147
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kalv-20230430_cal.xml EX-101.CAL 62559
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kalv-20230430_pre.xml EX-101.PRE 346902
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kalv-20230430_def.xml EX-101.DEF 161389
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kalv-20230430.xsd EX-101.SCH 53225
74 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20230430_htm.xml XML 1899449
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-K | Act: 34 | File No.: 001-36830 | Film No.: 231077958
SIC: 2834 Pharmaceutical Preparations